Shanghai Liyi Pharmaceutical Technology

Shanghai Liyi Pharmaceutical Technology is a Chinese pharmaceutical company established in 2011 that specializes in the import registration, agency, and development of high-quality therapeutics and health products. The company achieved a significant regulatory milestone in November 2025 with the National Medical Products Administration (NMPA) approval of its Class 5.1 drug, Azulvig (sildenafil citrate oral suspension), for the treatment of erectile dysfunction. Azulvig represents the first approved oral suspension for erectile dysfunction in China, offering a novel liquid formulation that allows for precise, personalized dosage adjustments and improved convenience over traditional solid tablets. Beyond its core focus on men's health, Shanghai Liyi Pharmaceutical Technology collaborates with international partners to introduce innovative medical and health products into the Chinese market.